- Obama military strategy too weak for future security, panel reports
- Sen. Tom Coburn vows to slow down budget-busting bills ahead of recess
- Obama fantasizes about more executive power, signs new order on federal contractors
- Clintons call Klein, Halper, Kessler ‘a Hat Trick of despicable actors’: report
- Boehner accuses Obama of ‘legacy of lawlessness’
- Pro-marijuana group claims responsibility for Brooklyn Bridge flag swap
- Young adults shun Obamacare mostly due to cost: survey
- Stabbing attack on transgender girl, 15, was ‘bias motivated,’ police say
- LGBT adults still lean overwhelmingly toward Democratic Party
- Lawmakers rattled by Syria genocide horrors, call on Obama to act
FDA admits mistake in approving implant
Question of the Day
The Food and Drug Administration issued an unprecedented “mea culpa” Thursday, saying it made a mistake in approving a knee implant against the advice of its scientific reviewers.
The announcement comes a year after the agency first acknowledged that its decision to approve the Menaflex implant, made by ReGen Biologics, was influenced by outside pressure, including lobbying by four Democratic lawmakers from the company’s home state of New Jersey.
The 2008 decision to approve the implant was made despite protests by FDA scientists that Menaflex - which reinforces damaged knee tissue - provides little, if any, benefit to patients.
FDA officials vowed last fall to revisit the decision made under President George W. Bush, after congressional investigators accused the agency of being too cozy with the companies it regulates. Since the device’s approval, the top two device regulators who oversaw Menaflex’s review have left the agency.
The four New Jersey Democratic lawmakers - Reps. Frank Pallone Jr. and Steven R. Rothman, and Sens. Robert Menendez and Frank R. Lautenberg - each had appealed to the FDA on ReGen’s behalf, according to accounts last year from Mr. Rothman and spokesmen for the three others.
In a statement Thursday, the FDA said it is taking steps to revoke Menaflex’s approval, although it also plans to meet with the company to discuss what data would be needed to prove the device is actually safe and effective.
ReGen, based in Hackensack, N.J., asked the FDA in 2005 to approve its device under the so-called “510k system,” which allows speedy approval for devices that are similar to products already on the market.
ReGen argued that the Menaflex was comparable to shoulder joint implants sold by Johnson & Johnson, Stryker and other companies. FDA scientists repeatedly rejected that argument, saying the device should go through a more rigorous process that requires patient testing.
The head of FDA’s device division overruled those scientists in late 2008. The agency said Thursday they were actually correct and that Menaflex is “technologically dissimilar from devices already on the market.”
ReGen Chief Executive Gerald Bisbee said in a statement the company is “weighing its options” for Menaflex, adding that “there has never been a safety issue associated with the device.”
TWT Video Picks
By James A. Lyons Jr.
The president has shifted alliance from friend to enemy
- Inside the Ring: Israel surprised by Hamas tunnel network
- Army's 3-D printed bombs to create 'a whole new universe' of lethal capabilities
- Chicken pox outbreak puts illegal immigrant facility on lockdown
- GOP leaders delay border bill, leave Obama in control
- Report: 40% of weapons sent to Afghanistan are unaccounted for
- CIA admits improperly hacking Senate computers in search of Bush-era information
- CRUZ: A tale of two hospitals: One in Israel, one in Gaza
- Lois Lerner hated conservatives, new emails show
- Catholic League slams Obama: 'Do Christian lives mean so little to you?'
- U.S. troops told not to eat, drink in front of Muslims during Ramadan
Obama's biggest White House 'fails'
Celebrities turned politicians
Athletes turned actors
20 gadgets that changed the world